Holen Sie sich die Stockscreener-App
0.90
12.50%
0.10
Finanzdaten der Eagle Pharmaceuticals Inc-Aktie (EGRX)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2023-06-30 | 2023-03-31 |
| Periodenlänge | 3 Monate | 3 Monate |
| Revenues |
2.50%
64.65
|
66.31 |
| Cost Of Revenue |
2.55%
16.86
|
17.30 |
| Gross Profit |
2.48%
47.79
|
49.01 |
Operating Expenses
|
0.68%
37.48
|
37.23 |
| Interest Income/Expense |
4.49%
1.448
|
1.516 |
| Benefits Costs and Expenses |
1.29%
55.35
|
56.07 |
| Costs And Expenses |
0.35%
54.34
|
54.53 |
| Operating Income/Loss |
12.48%
10.30
|
11.77 |
| Nonoperating Income/Loss |
34.76%
-1.006
|
-1.542 |
| Income/Loss From Continuing Operations Before Tax |
9.12%
9.298
|
10.23 |
| Income Tax Expense/Benefit |
7.74%
4.134
|
4.481 |
| Income/Loss From Continuing Operations After Tax |
10.19%
5.164
|
5.75 |
|
Net Income/Loss
|
10.19%
5.164
|
5.75 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- |
| Attributable To Noncontrolling Interest |
-
|
- |
| Basic Average Shares |
0.24%
13.09
|
13.06 |
| Diluted Average Shares |
0.01%
13.15
|
13.15 |
| Basic Earnings Per Share |
11.36%
0.39
|
0.44 |
| Diluted Earnings Per Share |
11.36%
0.39
|
0.44 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- |
0.57%
3.76%
Kapitalisierung:
|
Volumen (24h):